The global neutropenia treatment market to grow at a CAGR of 4.45% during the period 2017-2021.
The report, Global Neutropenia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms. Decrease in the neutrophil count in blood makes a patient susceptible to infections and may even prove fatal. Therefore, the condition requires immediate prophylaxis.
The global neutropenia treatment market has been primarily dominated by the use of biologics and biosimilars for its prevention and cure. However, with the advances in pharmaceutical science and technology, vendors have gained a better understanding of the etiology and epidemiology of disease, thereby paving the path for development of novel therapeutics. Similarly, innovation of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals, with immune-boosting effects, is likely to revolutionize the therapeutic regimen for neutropenia.